CTMX:NASDAQ, CytomX Therapeutics, Inc.
CTMX stock overview
CytomX Therapeutics, Inc. (CTMX:NASDAQ) closed at $2.19 on November 6, 2026,
up 2.34% on the day.
The stock trades 73.3% below its 52-week high of $8.21
and 3.8% above its 52-week low of $2.11.
Over the past year, it lost 39.5%.
CytomX Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
Key figures
- Price
- $2.19
- Day change
- +2.34%
- Volume
- 2,727,215
- Average volume
- 3,709,445
- Market cap
- 477M+
- 52-week range
- $2.11 – $8.21
- 50-day average
- $2.74
- 200-day average
- $3.82
Price action over the past year
In 252 trading sessions since November 6, 2025, CTMX closed higher on 108 days (43%).
Its best day was March 16, 2026 (+44.23%) and its worst was March 18, 2026 (-19.27%).
The stock moved 10% or more in a single session 10 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
CTMX news
-
Nov 6, 2026:
CytomX (CTMX) Q3 2026 Earnings Call Transcript
-
Nov 6, 2026:
CytomX Therapeutics Q3 Earnings Call Highlights
-
Nov 6, 2026:
CytomX Matches On EPS, But Varseta-M Data Slips To 2027 Shift The Burden To January
-
Nov 5, 2026:
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
-
Nov 5, 2026:
CytomX Therapeutics: Q3 Earnings Snapshot
-
Nov 5, 2026:
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
-
Nov 4, 2026:
Qiagen (QGEN) Surpasses Q3 Earnings and Revenue Estimates
-
Nov 2, 2026:
CytomX Therapeutics to Present at Upcoming November Investor Conferences
About CytomX Therapeutics, Inc.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
Similar stocks
Find more stocks like CTMX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.